ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy

Kojiro Omiya¹, Atsushi Oba^#^{2

3

4}, Kota Sugiura¹, Aya Maekawa^{1

5}, Takafumi Mie⁶, Kosuke Kobayashi¹, Yoshihiro Ono¹, Hiromichi Ito¹, Yosuke Inoue¹, Yu Takahashi^#⁷

Affiliations

¹ Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
² Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
³ Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
⁴ Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. atsushi.oba@jfcr.or.jp.
⁵ Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
⁶ Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
⁷ Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. yu.takahashi@jfcr.or.jp.

^# Contributed equally.

Kojiro Omiya et al. Ann Surg Oncol. 2025 Aug.

. 2025 Aug;32(8):5434-5435.

doi: 10.1245/s10434-025-17458-8. Epub 2025 May 21.

Kojiro Omiya¹, Atsushi Oba^#^{2

3

4}, Kota Sugiura¹, Aya Maekawa^{1

5}, Takafumi Mie⁶, Kosuke Kobayashi¹, Yoshihiro Ono¹, Hiromichi Ito¹, Yosuke Inoue¹, Yu Takahashi^#⁷

¹ Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
² Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
³ Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan. atsushi.oba@jfcr.or.jp.
⁴ Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. atsushi.oba@jfcr.or.jp.
⁵ Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
⁶ Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
⁷ Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. yu.takahashi@jfcr.or.jp.

^# Contributed equally.

No abstract available

Conflict of interest statement

DISCLOSURES: There are no conflicts of interest.

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (version 3. 2024). Retrieved Accessed 15 December 2024. at https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf .
1. Oba A, Del Chiaro M, Satoi S, et al. New criteria of resectability for pancreatic cancer: a position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci. 2022;29:725–31. - DOI - PubMed
1. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11. - DOI - PubMed
1. Omiya K, Oba A, Sugiura K, et al. Resectable pancreatic cancer with CA19-9 >500 U/mL: a biological indicator for survival benefit with intensive neoadjuvant chemotherapy. Ann Surg Oncol. 2025. https://doi.org/10.1245/s10434-025-17407-5 . - DOI - PubMed
1. Omiya K, Oba A, Inoue Y, et al. Serum DUPAN-2 could be an alternative biological marker for CA19-9 nonsecretors with pancreatic cancer. Ann Surg. 2023;277:e1278–83. - DOI - PubMed